Celgene Corporation (CELG) Receives Daily News Sentiment Rating of 0.20
News articles about Celgene Corporation (NASDAQ:CELG) have been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celgene Corporation earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.32082991872 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Celgene Corp (CELG) Breaks Through Support at $134.38 (mysmartrend.com)
- Biotech Breakouts Suggest It Is Time to Buy (finance.yahoo.com)
- Celgene’s Revlimid Witnessed High Growth in 2Q17 (finance.yahoo.com)
- Why BeiGene Soared 56.6% In July (fool.com)
- Hawaii Receives Approximately $477,000 in Settlement with Drug Manufacturer (damontucker.com)
CELG has been the topic of a number of research analyst reports. Jefferies Group LLC reissued a “buy” rating and issued a $154.00 price target on shares of Celgene Corporation in a research note on Tuesday, April 11th. Robert W. Baird reissued an “outperform” rating and issued a $162.00 price target on shares of Celgene Corporation in a research note on Wednesday, April 19th. Barclays PLC reissued an “equal weight” rating and issued a $125.00 price target (up from $120.00) on shares of Celgene Corporation in a research note on Sunday, April 23rd. Cann reissued a “buy” rating on shares of Celgene Corporation in a research note on Thursday, April 27th. Finally, Cantor Fitzgerald set a $159.00 price target on Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, April 27th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-three have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $147.06.
Shares of Celgene Corporation (CELG) traded up 0.22% during midday trading on Wednesday, hitting $135.57. The stock had a trading volume of 3,085,703 shares. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $139.00. The firm has a 50-day moving average of $132.00 and a 200 day moving average of $123.32. The firm has a market cap of $106.06 billion, a PE ratio of 41.99 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.44 EPS. On average, analysts expect that Celgene Corporation will post $7.32 earnings per share for the current year.
In other Celgene Corporation news, Director Gilla Kaplan sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the completion of the transaction, the director now owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now directly owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 235,255 shares of company stock valued at $31,377,042. Insiders own 0.95% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Celgene Corporation (CELG) Receives Daily News Sentiment Rating of 0.20” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/celgene-corporation-celg-receives-daily-news-sentiment-rating-of-0-20/1466525.html.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.